Notably, we have identified HYP as a novel USP18 inhibitor, which sensitizes cancer cells to existing targeted therapies (sorafenib and regorafenib) by directly targeting the IBB1 domain (Fig. 8). The gene discussed is USP18; the disease is cancer.